Rethinking back pain research
25 June 2026
The AO Research Institute (ARI) plays a central role in advancing musculoskeletal care through focused research and translational innovation. Its work supports the development of improved diagnostics, personalized treatments, and regenerative solutions aligned with clinical needs.
A key area of focus is the development of bioreactor systems and in vitro models, which replicate physiological conditions of bone, cartilage, and intervertebral discs. These models allow researchers to evaluate new therapeutic approaches under controlled, clinically relevant conditions, helping bridge the gap between laboratory research and patient care.
In parallel, the institute is advancing biomedical development and smart orthopaedics. The AO Fracture Monitor enables continuous, objective monitoring of bone healing without repeated imaging. Clinical studies indicate its potential to support prediction of healing outcomes and fixation failure, contributing to more individualized treatment strategies.
The ARI is also developing tissue-specific biomaterials, including porous scaffolds for bone, hydrogels for cartilage, and injectable systems for intervertebral discs. Complementary work on local antibiotic drug delivery systems aims to enhance therapeutic efficacy while minimizing systemic effects.
To ensure clinical relevance, the ARI follows a structured translational pathway—from in vitro validation to preclinical testing and clinical readiness. This approach supports safety, quality, and alignment with regulatory requirements.
Through these efforts, the ARI contributes to advancing musculoskeletal care, leading to more validated solutions, fewer complications, and better quality of life for patients worldwide.
Learn more about the ARI’s research programs:
Regenerative Orthopaedics
Biomedical Development
Preclinical Services
A key area of focus is the development of bioreactor systems and in vitro models, which replicate physiological conditions of bone, cartilage, and intervertebral discs. These models allow researchers to evaluate new therapeutic approaches under controlled, clinically relevant conditions, helping bridge the gap between laboratory research and patient care.
In parallel, the institute is advancing biomedical development and smart orthopaedics. The AO Fracture Monitor enables continuous, objective monitoring of bone healing without repeated imaging. Clinical studies indicate its potential to support prediction of healing outcomes and fixation failure, contributing to more individualized treatment strategies.
The ARI is also developing tissue-specific biomaterials, including porous scaffolds for bone, hydrogels for cartilage, and injectable systems for intervertebral discs. Complementary work on local antibiotic drug delivery systems aims to enhance therapeutic efficacy while minimizing systemic effects.
To ensure clinical relevance, the ARI follows a structured translational pathway—from in vitro validation to preclinical testing and clinical readiness. This approach supports safety, quality, and alignment with regulatory requirements.
Through these efforts, the ARI contributes to advancing musculoskeletal care, leading to more validated solutions, fewer complications, and better quality of life for patients worldwide.
Learn more about the ARI’s research programs:
Regenerative Orthopaedics
Biomedical Development
Preclinical Services